These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 17868007)
1. The PRoFESS trial: future impact on secondary stroke prevention. Diener HC Expert Rev Neurother; 2007 Sep; 7(9):1085-91. PubMed ID: 17868007 [TBL] [Abstract][Full Text] [Related]
2. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Diener HC; Sacco R; Yusuf S; ; Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887 [TBL] [Abstract][Full Text] [Related]
6. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610 [TBL] [Abstract][Full Text] [Related]
7. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Diener HC; Sacco RL; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW; Lancet Neurol; 2008 Oct; 7(10):875-84. PubMed ID: 18757238 [TBL] [Abstract][Full Text] [Related]
8. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW; N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638 [TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Hankey GJ Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741 [TBL] [Abstract][Full Text] [Related]
10. What is better antiplatelet agent to prevent recurrent stroke? Wadiwala MF; Kamal AK J Pak Med Assoc; 2012 Sep; 62(9):976-7. PubMed ID: 23139991 [TBL] [Abstract][Full Text] [Related]
11. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Jamieson DG; Parekh A; Ezekowitz MD J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet agents and randomized trials. Diener HC Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669 [TBL] [Abstract][Full Text] [Related]
13. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention. Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182 [No Abstract] [Full Text] [Related]
14. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. Simmons BB; Yeo A; Fung K; ; Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455 [TBL] [Abstract][Full Text] [Related]
15. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. Chairangsarit P; Sithinamsuwan P; Niyasom S; Udommongkol C; Nidhinandana S; Suwantamee J J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S148-54. PubMed ID: 16858953 [TBL] [Abstract][Full Text] [Related]
16. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R; Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679 [TBL] [Abstract][Full Text] [Related]
17. A review of therapeutic strategies for risk reduction of recurrent stroke. Phillips RA Prog Cardiovasc Dis; 2008; 50(4):264-73. PubMed ID: 18156005 [TBL] [Abstract][Full Text] [Related]
18. Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial. Estol CJ; Bath PM; Gorelick PB; Cotton D; Martin RH; Int J Stroke; 2014 Oct; 9 Suppl A100():43-7. PubMed ID: 24636673 [TBL] [Abstract][Full Text] [Related]